NCT06643741 is a clinical trial in Preeclampsia (PE), sponsored by Sequenom, Inc..

Who is sponsoring NCT06643741?

NCT06643741 is sponsored by Sequenom, Inc..

What condition does NCT06643741 study?

NCT06643741 studies Preeclampsia (PE).

Is NCT06643741 still recruiting?

NCT06643741 is currently recruiting now. Last updated 23 January 2026.

Last reviewed 2026-01-23 · How we verify

NCT06643741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Invasive Preeclampsia Screening and Biobank

Recruiting now Last updated 23 January 2026

What this trial tests

trial in Preeclampsia (PE) in 6,550 participants. Currently enrolling.

Timeline

2 February 2025

Primary endpoint
1 June 2026

1 July 2026

Quick facts

Lead sponsor	Sequenom, Inc.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	6,550
Start date	2 February 2025
Primary completion	1 June 2026
Estimated completion	1 July 2026
Sites	21 locations across United States

Conditions studied

Preeclampsia (PE) — all drugs for Preeclampsia (PE) →

Sponsor

Sequenom, Inc.

Who can join

18 and older, female only, with Preeclampsia (PE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Preeclampsia (PE)

Currently open trials in the same condition.

NCT07015203 — The Combined First Trimester Screening · recruiting
NCT06802861 — Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclam · recruiting
NCT07356817 — Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications · recruiting
NCT02989025 — Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia · Phase 2 · recruiting

Other Sequenom, Inc. trials

Trials by the same sponsor.

NCT06008457 — Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit · completed
NCT04595201 — Clinical Follow-up of Pregnant Subjects Undergoing NIPT · recruiting
NCT03631225 — The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis · active not recruiting
NCT03810144 — Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test · completed
NCT04364503 — Compliant Analysis of Patient Samples and Data · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06643741 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sequenom, Inc.
Last refreshed: 23 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06643741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing